Moxifloxacin Population Pharmacokinetics in Patients with Pulmonary Tuberculosis and the Effect of Intermittent High-Dose Rifapentine

We described the population pharmacokinetics of moxifloxacin and the effect of high-dose intermittent rifapentine in patients with pulmonary tuberculosis who were randomized to a continuation-phase regimen of 400 mg moxifloxacin and 900 mg rifapentine twice weekly or 400 mg moxifloxacin and 1,200 mg...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Zvada, Simbarashe P., Denti, Paolo, Geldenhuys, Hennie, Meredith, Sandra, van As, Danelle, Hatherill, Mark, Hanekom, Willem, Wiesner, Lubbe, Simonsson, Ulrika S. H., Jindani, Amina, Harrison, Thomas, McIlleron, Helen M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2012
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3421597/
https://ncbi.nlm.nih.gov/pubmed/22585223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00404-12
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi